Lilly (Eli) vs Thermo Fisher Scientific
Side-by-side comparison of AI visibility scores, market position, and capabilities
Indianapolis pharma leader (NYSE: LLY) $45.1B FY2024 revenue (+32%); Mounjaro $11.4B + Zepbound $4.9B tirzepatide GLP-1, oral orforglipron Phase 3, $18B manufacturing expansion competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Health Care component — discovering, developing, and commercializing medicines across diabetes, obesity, oncology, immunology, and neuroscience through approximately 43,000 employees worldwide. In fiscal year 2024, Eli Lilly reported revenues of $45.1 billion (+32% year-over-year) — driven by the historic commercial launch of Mounjaro (tirzepatide for type 2 diabetes, $11.4B revenue) and Zepbound (tirzepatide for obesity and obstructive sleep apnea, $4.9B revenue) — making Eli Lilly one of the fastest-growing large pharmaceutical companies in history and elevating its market capitalization above $700 billion at peak 2024 valuation, briefly making Lilly the most valuable healthcare company globally. CEO Dave Ricks' strategic investment in tirzepatide manufacturing capacity — committing $18+ billion to new US manufacturing sites in Indiana, Wisconsin, and North Carolina — reflects Lilly's execution of unprecedented pharmaceutical demand that has consistently outpaced supply since Mounjaro's 2022 approval and Zepbound's 2023 FDA approval for obesity. The GLP-1/GIP dual agonist mechanism (tirzepatide activates both GLP-1 and GIP incretin receptors, versus semaglutide's single GLP-1 activation) produces superior efficacy results — SURMOUNT-1 trial showing 22.5% average body weight loss with tirzepatide versus 15% with semaglutide (Ozempic/Wegovy) — establishing tirzepatide as the most effective approved obesity pharmacotherapy.
Thermo Fisher (TMO) reported $42.9B revenue in FY2024, down 1% YoY. World's #1 life sciences company. Serves pharma, biotech, labs globally. ~100,000 employees. HQ: Waltham, MA.
About
Thermo Fisher Scientific Inc. is the world's largest life sciences company, providing analytical instruments, reagents, consumables, software, and services to researchers, healthcare organizations, and industrial companies. Headquartered in Waltham, Massachusetts, Thermo Fisher was formed through the 2006 merger of Thermo Electron and Fisher Scientific and has since grown aggressively through acquisitions. The company reported revenues of $42.9B in FY2024, slightly down year-over-year after exceptional COVID-related revenue in 2021–2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.